| 3.86 -0.01 (-0.26%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5  |
1-year : | 5.69 |
| Resists | First : | 4.28 |
Second : | 4.88 |
| Pivot price | 4.25 |
|||
| Supports | First : | 3.32 |
Second : | 2.77 |
| MAs | MA(5) : | 3.98 |
MA(20) : | 4.13 |
| MA(100) : | 3.78 |
MA(250) : | 3.05 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 11 |
D(3) : | 18.5 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 5.78 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRWD ] has closed above bottom band by 12.8%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.02 - 4.04 | 4.04 - 4.07 |
| Low: | 3.74 - 3.77 | 3.77 - 3.79 |
| Close: | 3.81 - 3.86 | 3.86 - 3.9 |
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Thu, 16 Jul 2026
Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Tue, 14 Jul 2026
Ironwood’s 30-year medical chief retires as Phase 3 trial recruits - Stock Titan
Tue, 14 Jul 2026
Ironwood Pharmaceuticals (IRWD) Appoints New CMO as Leadership T - GuruFocus
Mon, 13 Jul 2026
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap (NASDAQ:IRWD) - Seeking Alpha
Thu, 09 Jul 2026
Ironwood (IRWD) finance chief sells 127,890 shares in 10b5-1 stock plan - Stock Titan
Sat, 04 Jul 2026
Enterprise value to EBIT forward of Ironwood Pharmaceuticals, Inc. – NASDAQ:IRWD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 165 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 98.8 (%) |
| Shares Short | 16,230 (K) |
| Shares Short P.Month | 15,020 (K) |
| EPS | 0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.33 |
| Profit Margin | 28.2 % |
| Operating Margin | 68 % |
| Return on Assets (ttm) | 33.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 158.8 % |
| Gross Profit (p.s.) | 1.65 |
| Sales Per Share | 2.19 |
| EBITDA (p.s.) | 1.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 112 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | 6.54 |
| PEG Ratio | 0 |
| Price to Book value | -2.93 |
| Price to Sales | 1.75 |
| Price to Cash Flow | 5.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|